Sandbox Reserved 1095

Functions

See also : Angiotensin_II_receptor_type_1 on Wikipedia

History

Discovery of angiotensin receptors

Researchers suspected since 70s the existence of different angiotensin receptors. However, tools to identify those distinct trans-membrane receptors became available ten years later. Receptors binding assays identified angiotensin receptors in vitro using radioactive angiotensin. Results showed several types of angiotensin receptors, found in different tissues. The main receptors are AT1 and AT2 ^[1].

Nomenclature

Three labs discovered in the same time these two angiotensin receptors and proposed their own nomenclature, leading to confusion. To avoid this, a group of researchers met in Baltimore in 1991 to define a coherent nomenclature. Under the presidency of Merlin Bumpus, a common ground has been found and the angiotensin receptors has been classified into two groups called AT1 and AT2 receptors. ^[2].

Recent studies

Finally, around 2015, researchers have found the crystal structure of the receptor in complex with its antagonist ZD7155 and with an inverse agonist olmesartan^[3]. X-ray cryogenic-crystallography has been used. They have found similar conformation of the receptor when it is linked to the antagonist or to the inverse agonist. They have also found conserved molecular recognition modes. To complete this discovery, they have realized some experiments with mutants to identify the different residues which interact with the ligand.

Structure (function relationship)

Primary and secondary structure

Human angiotensin receptor consists in a 376 amino acid string ^[4]. The protein is composed of 18 and 3 . Moreover, 7 alpha helix are made of a majority of hydrophobic amino acids and these helix are long enough to cross the membrane. These helix create an which is situated into the membrane. The human angiotensin receptor is therefore an alpha helical trans-membrane protein.

Ligand binding pocket

In the extracellular environment, there is a beta-hairpin in conjugation with two extracellular disulfure bridges. This structure is responsible for the opening and the locking of the ligand binding pocket ^[5]. The ligand goes into an created into the membrane thanks to the 7 alpha helix which create a gate between the membrane and the extracellular environment.

G protein-binding site

When the angiotensin II binds to the angiotensin receptor in the ligand binding pocket, the conformation of the trans-membrane domain changes to create a cytosolic cleft for the binding and activation of G proteins. In this cleft, several conserved residues can be found, which form functional motifs present in all GPCRs ^[6].

Interaction with drugs

Olmesartan, candesartan, telmisartan, and valsartan

Olmesartan anchored to ATR1 by the residues , and . Those three amino acids seem to play an important role in the binding of the drug to AT1R, thanks to the formation of extensive networks of hydrogen bonds and salt bridges with the ligand ^[7].

Many drugs used to cure diseases linked with the angiotensin receptor contain a tetrazole group. Studies showed that tetrazole plays an important role in the binding with AT1R.

 : an important role for AngII binding

Interaction with other GPCRs

It has been showed that AT1Rs were also able to bind with other GPCRs to form homo- or heterodimers. Those interactions can modify the sensitivity of the receptor, which leads to different physiological and pathological conditions than the GPCR monomer ^{[8] [9]}.

Application in the therapeutic field

Since angiotensin receptor is involved in the renin-angiotenisin system, it represents a target of choice to cure some diseases like hypertension or heart failure. An over-stimulation of this receptor seems to be involved in hypertension, coronary artery disease, cardiac hypertrophy, heart failure, arrhythmia, stroke, diabetic nephropathy and ischemic heart and renal diseases ^[10].

Several anti-hypertensive drugs are targeting the angiotensin receptor in order to block it. This is the case for drugs called angiotensin receptor blockers (ARBs) like olmesartan, candesartan, and losartan. One of the common characteristic they share is their biphenyl-tetrazole scaffold.